• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Erdotin
    / Megapharm

    Active Ingredient
    Erdosteine 300 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    20 X 300 mg

    not in the basket chart 27740 5532


    1 capsule 2-3 times a day, per os.


    Mucolitic agent in acute and chronic respiratory diseases.


    Known individual hypersensitivity towards the product or any of the excipients.
    Patients with active peptic ulcer.
    Because of a possible interference of the product metabolites with the methionine metabolism, ERDOTIN is contraindicated in patients suffering from hepatic cirrhosis and deficiency of the cystathionine-synthetase enzyme.
    Since there are no data in patients with creatinine clearance < 25 ml/min or with severe liver failure, the use of erdosteine is not recommended in these patients.

    Special Precautions


    Side Effects

    Less than 1 in 1,000 can expect to get gastrointestinal undesirable effects.
    See prescribing information for full details.

    Drug interactions

    No harmful interactions with other drugs have been reported and the product can therefore be administered together with antibiotics and bronchodilators (theophylline or beta-2-mimetics, cough sedatives, etc…).

    Pregnancy and Lactation

    The safety of erdosteine in pregnancy has not been established, therefore, as with all new drugs, its use is not recommended. Equally, its use is not recommended during lactation.


    With dosages exceeding those recommended (1200 mg/die) sweating, vertigo and flushing have been observed.

    Edmond Pharma
    Licence holder